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Increasing the Use of End Tidal Carbon Dioxide (ETCO2) for Moderate Sedation
BACKGROUND
• Short acting analgesia and sedation medications are
used during many procedures in the Emergency
Department (ED)
• Patients require close monitoring for abnormal vital
signs and other adverse occurrences, such as
respiratory depression and apnea
• Use of ETCO2 is recommended by the Emergency
Nurses Association (ENA) for moderate sedation
• ENA evidence-based Clinical Practice Guideline
(2015) determined that capnography during
moderate sedation detects respiratory depression
and apnea faster than vital signs, pulse oximetry,
and clinical assessment during short acting
analgesia and sedation

LOCAL CONTEXT
• Results of Emergency Care Center (ECC) medical
record audits (9/1/19-7/30/20) found that only
23% of patients undergoing moderate sedation
had ETCO2 used during the procedure

PURPOSE
• Increase the utilization of ETCO2 during moderation
sedation procedures. This will allow earlier
identification of deterioration and allow RNs to
intervene quicker
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METHODS
Design: Evidence-based quality improvement
Participants: Emergency Care Center RNs
Procedure:
• Education provided to RNs using assigned modules
and emailed power point presentations on the
use, setup, indications and interventions of ETCO2
for patients receiving moderate sedation
• Self-auditing tool
• Developed
• Completed by primary RN performing a
moderate sedation procedure
• Contents:
• Was a consent form signed for the
procedure?
• Was ETCO2 used? If not, what is the reason?
• Was ETCO2 documented per policy? For how
long?
• Was there an adverse event?
• Follow up and coaching was done when ETCO2
was not used or documented per policy
• Collection and Analysis: A minimum of six audits
were preformed monthly on the records of
patients receiving moderate sedation and use of
ETCO2

RESULTS
• 23% of all audited charts between 9/19 -7/20 had
ETCO2 documented per policy
• ETCO2 education was sent out in January, February
and July 2020. The “Self Auditing Tool” was
implemented in Feb 2021
• There was only a 30% use of ETCO2 for the month of
Feb 2021, but for months March through July 2021,
use of ETCO2 increased to 67%
• Jan and Feb 2021 had 41% use, RNs citing machine
not available. In March, added two new machines
which may have contributed to the increase in use
and compliance
• ETCO2 use for July 2021 was 80%
• RNs noted and appropriately responded to
abnormal ETCO2. Patient condition stabilized with
return to baseline

IMPLICATIONS FOR PRACTICE/DISCUSSION
• The use of ETCO2 during moderate sedation is an
ENA Clinical Practice Guideline and best practice
• Following COVID-19, the ECC will begin to use ETCO2
in intubated patients to measure effectiveness of
compressions and as a measure of ROSC
• The opportunity exists to improve the use of ETCO2
for moderate sedation
• Patients who predominately mouth breath result in
the inability of nasal sensor to pick up ETCO2, this
may provide inaccurate readings

CONCLUSION
• The use of ETCO2 in theory and in practice is able
to detect respiratory depression faster than pulse
oximetry, allowing timely RN intervention with
excellent patient outcomes

